Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Other financing activities (2017 - 2025)

Conmed (CNMD) has disclosed Other financing activities for 15 consecutive years, with $4000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities fell 99.86% year-over-year to $4000.0, compared with a TTM value of $170000.0 through Dec 2025, down 94.0%, and an annual FY2025 reading of $170000.0, down 94.0% over the prior year.
  • Other financing activities was $4000.0 for Q4 2025 at Conmed, up from -$2.7 million in the prior quarter.
  • Across five years, Other financing activities topped out at $15.0 million in Q2 2022 and bottomed at -$14.7 million in Q4 2023.
  • Average Other financing activities over 5 years is $1.2 million, with a median of $1.4 million recorded in 2022.
  • The sharpest move saw Other financing activities soared 6295.24% in 2021, then tumbled 1143.11% in 2023.
  • Year by year, Other financing activities stood at $5.3 million in 2021, then tumbled by 73.19% to $1.4 million in 2022, then crashed by 1143.11% to -$14.7 million in 2023, then surged by 119.29% to $2.8 million in 2024, then plummeted by 99.86% to $4000.0 in 2025.
  • Business Quant data shows Other financing activities for CNMD at $4000.0 in Q4 2025, -$2.7 million in Q3 2025, and $3.4 million in Q2 2025.